MN-166 (ibudilast) will be part of the Phase III clinical trial on progressive multiple sclerosis subjects with secondary progressive MS without relapses.
multiple sclerosis (ms)
-
Read more »
-
June 14, 2019Read more »
Phase 2 clinical trial shows that ibudilast is linked to a 48% slowing in the progression of brain atrophy compared to placebo for patients with progressive MS.
-
November 29, 2018Read more »
In an exploratory study Ocrevus (ocrelizumab) slowed down loss of function in the upper extremities for patients with primary progressive multiple sclerosis (PPMS).
-
April 04, 2018Read more »
My father, who was a general practitioner before he retired, was with me when we heard the official report of the neurologist. Afterwards, sitting in the car, he had to digest the fact that both his son and daughter had multiple sclerosis.
-
January 29, 2018Read more »
The potential of neuroprotective agents for a whole new form of treatment.
-
Read more »
Ocrevus (ocrelizumab) was approved in the US by the FDA in March 2017 for the treatment of adults with relapsing or primary progressive forms of MS, based on three clinical trials.
-
Read more »
Get the latest news on MS research, the FDA approval of Ocrevus (ocrelizumab) for both relapsing and progressive forms of MS, insights and resources.
